Skip to main content
← All trials
Colonic NeoplasmsCancerGut healthBiologicalDrugPhase 3

What this study is

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

What's being tested

  • Dostarlimab

    Intervention · BIOLOGICAL

    Dostarlimab will be administered.

  • CAPEOX

    Intervention · DRUG

    CAPEOX will be administered.

  • FOLFOX

    Intervention · DRUG

    FOLFOX will be administered.

Study details

Official title
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Sponsor
GlaxoSmithKline
Conditions
Colonic Neoplasms · Neoplasms, Colon
Enrolling
892 people
Starts
2023-08-01
Est. completion
2031-03-27
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗